TREAT OA



Treat OA

Multi collaborative, integrated project trying to address the need for better treatment and diagnostics for osteoarthritis which is the most common cause of disability in Europe

Translational Research in Europe Applied Technologies for Osteoarthritis

-Treat OA-

Twin Research Department
King's College London
St Thomas' Hospital
Westminster Bridge Road
London SE1 7EH

Phone: +44 (0) 20 7188 6765
Fax: +44 (0) 20 7188 6718

E-mail: enquiries@treatoa.eu Website: www.treatoa.eu

TreatOA

Translational Research in Europe Applied Technologies for Osteoarthritis

SEVENTH FRAMEWORK PROGRAMME

THEME HEALTH

FP7-HEALTH-2007-2.4.5-1

SEVENTH FRAMEWORK PROGRAMME

Treat OA

TREAT-OA address the need for better treatment and diagnostics for osteoarthritis (OA) which is the most common cause of disability in Europe.

TREAT-OA represents a large-scale collaborative, integrated, trans-disciplinary project utilising a resource of 28,000 OA phenotyped subjects to address the generalisability and utility of genetic and biochemical risk factors throughout the EU and establish animal models for OA, helping to elucidate the pathogenetic mechanisms and possible intervention strategies aimed at delaying the onset of the disease.



Objectives

1. identify genes and biochemical markers for OA
2. Define roles of genes on OA onset and progression
3. identify targets for pharmacological intervention

Impact

- Improve general understanding of OA pathogenesis
- Develop new biochemical and genetic diagnostic markers for disease risk -> identify people at high risk
- Assess risk due to genetic and biochemical factors in Europe and other populations.
- Development of in vitro and in vivo assays to identify potential therapeutic targets
- Develop comprehensive technology platform new insights into pathogenesis of human OA

Work Packages



WP 1- Genome Wide Association Studies To Identify OA Risk Genes

WP 2—Generalisability of genes and biomarkers to various European populations: geographic diversity and environmental risk factors

WP3—Meta-analysis and Bioinformatics

WP4—Biochemical markers (BM) of OA progression and incidence

WP5 -Functional genomics: In vitro studies

WP6-Functional Genomics: in vivo studies and animal models of OA

WP7 -Functional Genomics: in vivo studies and animal models of OA

WP8– Risk Prediction

WP9– Drug Target screening

WP10 –Project Management

WP11-Dissemination

Partners

Collaborators - EU

Universities of :

Lund *Belgium*, Thessalia *Greece*, D&T Helsinki *Finland*, Jyvaskyla *Finland*, Newcastle *UK*, Estonia, *Santiago de Compostela Spain, and* Southampton General Hospital *UK*

Non EU

Riken *Japan*, Nanjing *China*, California *USA*—Niams *USA*, Queensland *Australia*, Tasmania Australia, Harvard *USA*